Stories that are getting the most attention from our readers in the last 24 hours.
A multicenter phase 3 randomized controlled trial enrolled 420 patients with advanced melanoma who had progressed after prior checkpoint inhibitor therapy, randomly assigning them to receive either the novel bispecific T-cell engager antibody targeting PD-1 and LAG-3 or standard chemotherapy. Responses were evaluated using RECIST criteria, with primary endpoints including objective response rate and progression-free survival. The antibody group achieved a 65% objective response rate, with many responses lasting over 12 months, significantly outperforming chemotherapy. This positions the treatment as a potential second-line option, reducing reliance on toxic chemotherapies and improving outcomes for refractory patients. Published in Nature Medicine on March 7, 2026.
The U.S. FDA has approved the first-ever gene therapy for spinal muscular atrophy (SMA) Type 1, a rare genetic muscle-wasting disease affecting infants. Developed by Novartis, the one-time intravenous treatment Zolgensma targets the root genetic cause, potentially halting progression in children under 6 months. Priced at $2.1 million per dose, it's expected to be covered by most U.S. insurers, marking a milestone in personalized medicine.
The U.S. Supreme Court issued a stay on March 9, 2026, temporarily blocking the deportation of former President Donald Trump pending further review of his legal challenges to a lower court ruling. The 5-4 decision came hours after a federal appeals court upheld an order for his removal over alleged violations of post-presidency foreign emoluments. This marks a rare intervention in a politically charged immigration enforcement case involving a former head of state.
Johnson & Johnson Consumer Health issued a voluntary recall of approximately 1.5 million bottles of Neutrogena Ultra Sheer and Aveeno Protect + Refresh sunscreen sprays after independent testing detected elevated levels of benzene, a known carcinogen, in some aerosol products. The recall affects sprays manufactured between November 2023 and February 2026, sold nationwide at retailers like Walmart, Target, and CVS. No illnesses have been reported, but consumers are urged to stop using and return products for refunds; lot numbers are listed on the FDA website.
The U.S. Federal Reserve maintained its benchmark interest rate at 4.75-5.00% in its March 2026 meeting, citing progress on inflation toward the 2% target but persistent risks from supply chain disruptions. Chair Jerome Powell noted that recent data shows core PCE inflation at 2.4%, down from peaks, but emphasized caution due to global energy volatility. The statement opens the door to rate cuts as early as June if employment remains stable.
A ProPublica investigation uncovered internal Secret Service emails from July 2024 showing agents dismissed warnings about a suspicious individual at the Butler, Pennsylvania rally where an assassination attempt on then-candidate Donald Trump occurred. The emails, obtained via FOIA, reveal supervisors overruled field agents' requests for drone surveillance and additional manpower due to staffing shortages. This accountability reporting highlights systemic failures that allowed the shooter to access a rooftop vantage point, resulting in one death and injuries.
Apple has rolled out iOS 19.1, featuring advanced AI-driven security enhancements to counter a surge in sophisticated cyberattacks targeting mobile users. The update includes real-time threat detection, automated phishing blocks, and encrypted data processing powered by on-device machine learning. This release comes after a week of high-profile breaches affecting millions, prompting urgent patches for iPhone and iPad users worldwide.
GamblingHarm.org's February 2026 report compiles data from over 50,000 online sports bettors surveyed nationwide using the Problem Gambling Severity Index (PGSI), a validated 9-question tool assessing gambling behaviors over the past year. Additional data draws from anonymized app usage logs from major platforms like DraftKings and FanDuel, covering 12 months through January 2026. Key findings show 7.4% of U.S. online sports bettors meet criteria for problem gambling, up 1.8 percentage points from 2025, affecting an estimated 2.8 million adults. This rise correlates with a 22% increase in monthly betting handle to $12.4 billion. The methodology ensures reliability through stratified sampling by state, age, and betting frequency, highlighting a public health concern amid sports betting's expansion to 45 states.
McKinsey Global Institute analyzed proprietary data from 800 multinational companies using econometric models, combined with U.S. Bureau of Labor Statistics occupational data and AI exposure simulations to assess generative AI's impact on work. The study projects generative AI could automate 45% of activities in knowledge-based jobs by 2028, particularly in administrative and creative roles. Key findings show targeted reskilling programs increase worker retention by 25% in AI-affected sectors and deliver 15% higher productivity for investing companies. This underscores reskilling's role in mitigating job displacement amid rapid AI adoption, providing evidence-based strategies for labor market adaptation.
LeBron James, the NBA's all-time leading scorer, announced his retirement on March 8, 2026, after 23 seasons, with his final years spent with the Los Angeles Lakers. The four-time champion reflected on his journey from Akron, Ohio, to global icon status in a press conference following a Lakers win. James leaves behind records in points, playoff appearances, and finals MVP awards, reshaping the league's narrative.
We use cookies to analyze site traffic and improve your experience. By clicking Accept, you consent to our use of analytics cookies. Privacy Policy
